Acadia Healthcare Company, Inc. (ACHC) stock
ACHCNasdaqServices-Specialty Outpatient Facilities, NECFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 7/3056% below fair value
$29.96+0.50 (+1.70%)
Close on Oct 30, 2026Market cap $2.79BP/E –Yield –
Earnings
Acadia Healthcare's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
Nov 4, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$865.80M
-0.4% on a year earlier
Adjusted earnings per diluted share, Q2 FY2026
$0.38
$0.83 a year earlier
Latest guidance
Raised
Jul 28, 2026 · 5 items
Quarterly results
Revenue and earnings per share from each of Acadia Healthcare's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026Expected | – | – | – | – | – |
| Q2 FY2026ended Jun 30, 2026 | Jul 28, 2026after the close | $865.80M | -0.4% | $0.12 | $0.38 | Release |
| Q1 FY2026ended Mar 31, 2026 | Apr 29, 2026after the close | $828.80M | +7.6% | $0.05 | $0.37 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 25, 2026before the open | $821.50M | +6.1% | -$13.02 | $0.07 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025after the close | $851.60M | +4.4% | $0.40 | $0.72 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025after the close | $869.20M | +9.2% | $0.33 | $0.83 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 12, 2025after the close | $770.50M | +0.3% | $0.09 | $0.40 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025after the close | $774.20M | +4.2% | $0.35 | $0.64 | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 30, 2024after the close | $815.60M | +8.7% | – | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024after the close | $796.00M | +8.8% | $0.85 | $0.91 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 1, 2024after the close | $768.10M | +9.1% | $0.83 | $0.84 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 27, 2024after the close | $742.80M | +10.0% | $0.63 | $0.85 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 2, 2023after the close | $750.30M | +12.5% | -$2.39 | $0.91 | Release |
| Q2 FY2023ended Jun 30, 2023 | Jul 27, 2023after the close | $731.30M | +12.2% | $0.79 | $0.92 | Release |
| Q1 FY2023ended Mar 31, 2023 | Apr 26, 2023after the close | $704.30M | +14.2% | $0.72 | $0.75 | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 27, 2023after the close | $675.30M | +13.8% | $0.67 | $0.74 | Release |
| Q3 FY2022ended Sep 30, 2022 | Oct 31, 2022after the close | $666.70M | +13.5% | $0.78 | $0.86 | Release |
| Q2 FY2022ended Jun 30, 2022 | Jul 27, 2022after the close | $651.70M | – | $0.88 | $0.91 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022after the close | $616.70M | – | $0.67 | $0.67 | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 28, 2022after the close | $593.50M | – | $0.77 | $0.81 | Release |
| Q3 FY2021ended Sep 30, 2021 | Oct 28, 2021after the close | $587.60M | – | $0.73 | $0.72 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 2, 2021after the close | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 29, 2021after the close | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 26, 2021after the close | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020after the close | – | – | – | – | Filing |
| Q2 FY2020ended Jun 30, 2020 | Aug 4, 2020after the close | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Acadia Healthcare's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Revenue | FY2026 | $3.40B – $3.45B | $3.37B – $3.45B | Raised | Jul 28, 2026 |
| RevenueGAAP | FY2026 | $3.37B – $3.45B | – | New | Feb 25, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $590.00M – $615.00M | $580.00M – $615.00M | Raised | Jul 28, 2026 |
| Adjusted EBITDAnon-GAAP | FY2026 | $575.00M – $610.00M | – | New | Feb 25, 2026 |
| Adjusted earnings per diluted sharenon-GAAP | FY2026 | $1.45 – $1.60 | $1.35 – $1.60 | Raised | Jul 28, 2026 |
| Adjusted earnings per diluted sharenon-GAAP | FY2026 | $1.30 – $1.55 | – | New | Feb 25, 2026 |
| Capital expenditures | FY2026 | $235.00M – $255.00M | $255.00M – $280.00M | Lowered | Jul 28, 2026 |
| Capital expenditures | FY2026 | $255.00M – $280.00M | – | New | Feb 25, 2026 |
| beds expected in 2026 | FY2026 | 500 – 700 | – | New | Nov 5, 2025 |
| Operating Cash Flow | FY2026 | $350.00M – $400.00M | $285.00M – $325.00M | Raised | Jul 28, 2026 |
Guidance vs results
The last range Acadia Healthcare gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| Q2 FY2026 | Adjusted earnings per diluted share | $0.30 – $0.40 | $0.38 | Within range |
| Q2 FY2026 | Revenue | $835.00M – $850.00M | $865.80M | Above range |
| Q1 FY2026 | Adjusted earnings per diluted share | $0.25 – $0.30 | $0.37 | Above range |
| Q1 FY2026 | Revenue | $820.00M – $830.00M | $828.80M | Within range |
| FY2025 | Adjusted earnings per diluted share | $2.35 – $2.45 | $2.02Σ4Q | Below range |
| FY2025 | Revenue | $3.28B – $3.30B | $3.31BΣ4Q | Above range |
| Q1 FY2025 | Revenue | $765.00M – $775.00M | $770.50M | Within range |
| Q1 FY2024 | Adjusted earnings per diluted share | $0.78 – $0.83 | $0.84 | Above range |
| Q1 FY2024 | Revenue | $775.00M – $785.00M | $768.10M | Below range |
| Q1 FY2023 | Adjusted earnings per diluted share | $0.70 – $0.74 | $0.75 | Above range |
| Q1 FY2023 | Revenue | $690.00M – $700.00M | $704.30M | Above range |
| Q1 FY2022 | Adjusted earnings per diluted share | $0.62 – $0.66 | $0.67 | Above range |
| Q1 FY2022 | Revenue | $600.00M – $610.00M | $616.70M | Above range |
Guidance history
Every forecast Acadia Healthcare put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Jul 28, 2026 | Capital expenditures | FY2026 | $235.00M – $255.00M | Lowered |
| Jul 28, 2026 | Adjusted EBITDA | FY2026 | $590.00M – $615.00M | Raised |
| Jul 28, 2026 | Adjusted earnings per diluted share | FY2026 | $1.45 – $1.60 | Raised |
| Jul 28, 2026 | Operating Cash Flow | FY2026 | $350.00M – $400.00M | Raised |
| Jul 28, 2026 | Revenue | FY2026 | $3.40B – $3.45B | Raised |
| Apr 29, 2026 | Capital expenditures | FY2026 | $255.00M – $280.00M | New |
| Apr 29, 2026 | Adjusted EBITDA | FY2026 | $580.00M – $615.00M | New |
| Apr 29, 2026 | Adjusted EBITDA | Q2 FY2026 | $142.00M – $152.00M | New |
| Apr 29, 2026 | Adjusted earnings per diluted share | FY2026 | $1.35 – $1.60 | New |
| Apr 29, 2026 | Adjusted earnings per diluted share | Q2 FY2026 | $0.30 – $0.40 | New |
| Apr 29, 2026 | Operating Cash Flow | FY2026 | $285.00M – $325.00M | New |
| Apr 29, 2026 | Revenue | FY2026 | $3.37B – $3.45B | New |
| Apr 29, 2026 | Revenue | Q2 FY2026 | $835.00M – $850.00M | New |
| Feb 25, 2026 | Capital expenditures | FY2026 | $255.00M – $280.00M | New |
| Feb 25, 2026 | Adjusted EBITDA | Q1 FY2026 | $130.00M – $137.00M | New |
| Feb 25, 2026 | Adjusted EBITDA | FY2026 | $575.00M – $610.00M | New |
| Feb 25, 2026 | Adjusted earnings per diluted share | Q1 FY2026 | $0.25 – $0.30 | New |
| Feb 25, 2026 | Adjusted earnings per diluted share | FY2026 | $1.30 – $1.55 | New |
| Feb 25, 2026 | Revenue | Q1 FY2026 | $820.00M – $830.00M | New |
| Feb 25, 2026 | Revenue | FY2026 | $3.37B – $3.45B | New |
| Nov 5, 2025 | Expansion capital expenditures | FY2025 | $505.00M – $515.00M | New |
| Nov 5, 2025 | Maintenance and IT capital expenditures | FY2025 | $105.00M – $115.00M | Lowered |
| Nov 5, 2025 | Adjusted EBITDA | FY2025 | $650.00M – $660.00M | New |
| Nov 5, 2025 | Adjusted earnings per diluted share | FY2025 | $2.35 – $2.45 | New |
| Nov 5, 2025 | Total bed additions | FY2025 | 945 – 1076 | New |
| Nov 5, 2025 | Tax rate | FY2025 | 22.5% – 23.5% | New |
| Nov 5, 2025 | Interest expense | FY2025 | $135.00M – $140.00M | New |
| Nov 5, 2025 | Depreciation and amortization expense | FY2025 | $190.00M – $195.00M | Raised |
| Nov 5, 2025 | Stock compensation expense | FY2025 | $33.00M – $38.00M | Lowered |
| Nov 5, 2025 | Operating cash flows | FY2025 | $400.00M – $425.00M | Raised |
| Nov 5, 2025 | Startup losses | FY2025 | $60.00M – $65.00M | Lowered |
| Nov 5, 2025 | beds expected in 2026 | FY2026 | 500 – 700 | New |
| Nov 5, 2025 | Revenue | FY2025 | $3.28B – $3.30B | New |
| Aug 5, 2025 | Expansion capital expenditures | FY2025 | $495.00M – $535.00M | Raised |
| Aug 5, 2025 | Maintenance and IT capital expenditures | FY2025 | $105.00M – $115.00M | Lowered |
| Aug 5, 2025 | Adjusted EBITDA | FY2025 | $675.00M – $700.00M | Lowered |
| Aug 5, 2025 | Adjusted earnings per diluted share | FY2025 | $2.45 – $2.65 | Lowered |
| Aug 5, 2025 | Total bed additions | FY2025 | 950 – 1000 | Raised |
| Aug 5, 2025 | Tax rate | FY2025 | 25% – 26% | Reaffirmed |
| Aug 5, 2025 | Same-facility volume growth | FY2025 | +2% – +3% | New |
| Aug 5, 2025 | Interest expense | FY2025 | $130.00M – $140.00M | Raised |
| Aug 5, 2025 | Depreciation and amortization expense | FY2025 | $185.00M – $195.00M | Raised |
| Aug 5, 2025 | Stock compensation expense | FY2025 | $40.00M – $45.00M | Lowered |
| Aug 5, 2025 | Operating cash flows | FY2025 | $460.00M – $485.00M | Raised |
| Aug 5, 2025 | Startup losses | FY2025 | $60.00M – $65.00M | Lowered |
| Aug 5, 2025 | net increase in Medicaid supplemental payments | FY2025 | $30.00M – $40.00M | Lowered |
| Aug 5, 2025 | Revenue | FY2025 | $3.30B – $3.35B | Lowered |
| May 12, 2025 | Expansion capital expenditures | FY2025 | $525.00M – $575.00M | New |
| May 12, 2025 | Maintenance and IT capital expenditures | FY2025 | $105.00M – $115.00M | Lowered |
| May 12, 2025 | Adjusted EBITDA | FY2025 | $675.00M – $725.00M | Reaffirmed |
| May 12, 2025 | Adjusted earnings per diluted share | FY2025 | $2.50 – $2.80 | Reaffirmed |
| May 12, 2025 | Total bed additions | FY2025 | 800 – 1000 | Reaffirmed |
| May 12, 2025 | Tax rate | FY2025 | 25% – 26% | New |
| May 12, 2025 | Interest expense | FY2025 | $130.00M – $140.00M | New |
| May 12, 2025 | Depreciation and amortization expense | FY2025 | $175.00M – $185.00M | Raised |
| May 12, 2025 | Stock compensation expense | FY2025 | $45.00M – $50.00M | Lowered |
| May 12, 2025 | Operating cash flows | FY2025 | $460.00M – $510.00M | Raised |
| May 12, 2025 | net increase in Medicaid supplemental payments | FY2025 | $0 – $15.00M | Lowered |
| May 12, 2025 | Revenue | FY2025 | $3.30B – $3.40B | New |
| Feb 27, 2025 | Expansion capital expenditures | FY2025 | $525.00M – $575.00M | New |
| Feb 27, 2025 | Maintenance and IT capital expenditures | FY2025 | $105.00M – $115.00M | Lowered |
| Feb 27, 2025 | Adjusted EBITDA | Q1 FY2025 | $130.00M – $135.00M | New |
| Feb 27, 2025 | Adjusted EBITDA | FY2025 | $675.00M – $725.00M | New |
| Feb 27, 2025 | Adjusted earnings per diluted share | FY2025 | $2.50 – $2.80 | New |
| Feb 27, 2025 | Total bed additions | FY2025 | 800 – 1000 | New |
| Feb 27, 2025 | Tax rate | FY2025 | 25% – 26% | New |
| Feb 27, 2025 | Interest expense | FY2025 | $130.00M – $140.00M | New |
| Feb 27, 2025 | Depreciation and amortization expense | FY2025 | $175.00M – $185.00M | Raised |
| Feb 27, 2025 | Stock compensation expense | FY2025 | $45.00M – $50.00M | Lowered |
| Feb 27, 2025 | Operating cash flows | FY2025 | $460.00M – $510.00M | Raised |
| Feb 27, 2025 | Revenue | Q1 FY2025 | $765.00M – $775.00M | New |
| Feb 27, 2025 | Revenue | FY2025 | $3.30B – $3.40B | New |
| Jul 31, 2024 | Expansion capital expenditures | FY2024 | $425.00M – $475.00M | Raised |
| Jul 31, 2024 | Maintenance and IT capital expenditures | FY2024 | $90.00M – $110.00M | Lowered |
| Jul 31, 2024 | Adjusted EBITDA | FY2024 | $735.00M – $765.00M | Narrowed |
| Jul 31, 2024 | Adjusted earnings per diluted share | FY2024 | $3.45 – $3.65 | Narrowed |
| Jul 31, 2024 | Total bed additions, excluding acquisitions | FY2024 | 1200 | Reaffirmed |
| Jul 31, 2024 | Tax rate | FY2024 | 24.5% – 25.5% | Reaffirmed |
| Jul 31, 2024 | Interest expense | FY2024 | $110.00M – $120.00M | Raised |
| Jul 31, 2024 | Depreciation and amortization expense | FY2024 | $150.00M – $160.00M | Raised |
| Jul 31, 2024 | Stock compensation expense | FY2024 | $40.00M – $45.00M | Lowered |
| Jul 31, 2024 | Operating cash flows | FY2024 | $525.00M – $575.00M | Raised |
| Jul 31, 2024 | Revenue | FY2024 | $3.18B – $3.23B | Lowered |
| May 1, 2024 | Expansion capital expenditures | FY2024 | $425.00M – $475.00M | Raised |
| May 1, 2024 | Maintenance and IT capital expenditures | FY2024 | $90.00M – $110.00M | Lowered |
| May 1, 2024 | Adjusted EBITDA | FY2024 | $730.00M – $770.00M | Reaffirmed |
| May 1, 2024 | Adjusted earnings per diluted share | FY2024 | $3.40 – $3.70 | Reaffirmed |
| May 1, 2024 | Total bed additions, excluding acquisitions | FY2024 | 1200 | Reaffirmed |
| May 1, 2024 | Tax rate | FY2024 | 24.5% – 25.5% | Reaffirmed |
| May 1, 2024 | Stock compensation expense | FY2024 | $40.00M – $45.00M | Lowered |
| May 1, 2024 | Interest expense | FY2024 | $110.00M – $120.00M | New |
| May 1, 2024 | Depreciation and amortization expense | FY2024 | $150.00M – $160.00M | Raised |
| May 1, 2024 | Operating cash flows | FY2024 | $525.00M – $575.00M | Raised |
| May 1, 2024 | Revenue | FY2024 | $3.18B – $3.25B | New |
| Feb 27, 2024 | Expansion capital expenditures | FY2024 | $425.00M – $475.00M | New |
| Feb 27, 2024 | Maintenance and IT capital expenditures | FY2024 | $90.00M – $110.00M | Lowered |
| Feb 27, 2024 | Adjusted EBITDA | Q1 FY2024 | $170.00M – $175.00M | New |
| Feb 27, 2024 | Adjusted EBITDA | FY2024 | $730.00M – $770.00M | New |
| Feb 27, 2024 | Adjusted earnings per diluted share | Q1 FY2024 | $0.78 – $0.83 | New |
| Feb 27, 2024 | Adjusted earnings per diluted share | FY2024 | $3.40 – $3.70 | New |
| Feb 27, 2024 | Total bed additions, excluding acquisitions | FY2024 | 1200 | New |
| Feb 27, 2024 | Tax rate | FY2024 | 24.5% – 25.5% | New |
| Feb 27, 2024 | Interest expense | FY2024 | $110.00M – $120.00M | New |
| Feb 27, 2024 | Depreciation and amortization expense | FY2024 | $150.00M – $160.00M | Raised |
| Feb 27, 2024 | Stock compensation expense | FY2024 | $40.00M – $45.00M | Lowered |
| Feb 27, 2024 | Operating cash flows | FY2024 | $525.00M – $575.00M | Raised |
| Feb 27, 2024 | Revenue | Q1 FY2024 | $775.00M – $785.00M | New |
| Feb 27, 2024 | Revenue | FY2024 | $3.18B – $3.25B | New |
| Nov 2, 2023 | Expansion capital expenditures | FY2023 | $300.00M – $350.00M | Raised |
| Nov 2, 2023 | Maintenance capital expenditures | FY2023 | $40.00M – $50.00M | Lowered |
| Nov 2, 2023 | IT capital expenditures | FY2023 | $35.00M – $45.00M | Lowered |
| Nov 2, 2023 | Adjusted EBITDA, excluding income from the PRF | FY2023 | $665.00M – $675.00M | Narrowed |
| Nov 2, 2023 | Adjusted earnings per diluted share, excluding income from the PRF | FY2023 | $3.33 – $3.43 | Narrowed |
| Nov 2, 2023 | Tax rate | FY2023 | 25% – 26% | Reaffirmed |
| Nov 2, 2023 | Interest expense | FY2023 | $82.00M – $85.00M | Raised |
| Nov 2, 2023 | Depreciation and amortization expense | FY2023 | $125.00M – $135.00M | Raised |
| Nov 2, 2023 | Stock compensation expense | FY2023 | $30.00M – $35.00M | Lowered |
| Nov 2, 2023 | Operating cash flows | FY2023 | $450.00M – $500.00M | Raised |
| Nov 2, 2023 | Revenue | FY2023 | $2.90B – $2.92B | Raised |
| Jul 27, 2023 | Expansion capital expenditures | FY2023 | $350.00M – $400.00M | Raised |
| Jul 27, 2023 | Maintenance capital expenditures | FY2023 | $40.00M – $50.00M | Lowered |
| Jul 27, 2023 | IT capital expenditures | FY2023 | $35.00M – $45.00M | Lowered |
| Jul 27, 2023 | Adjusted EBITDA | FY2023 | $655.00M – $685.00M | Raised |
| Jul 27, 2023 | Adjusted earnings per diluted share | FY2023 | $3.25 – $3.50 | Raised |
| Jul 27, 2023 | Tax rate | FY2023 | 25% – 26% | Reaffirmed |
| Jul 27, 2023 | Stock compensation expense | FY2023 | $30.00M – $35.00M | Lowered |
| Jul 27, 2023 | Interest expense | FY2023 | $82.00M – $85.00M | Lowered |
| Jul 27, 2023 | Depreciation and amortization expense | FY2023 | $125.00M – $135.00M | Raised |
| Jul 27, 2023 | Operating cash flows | FY2023 | $450.00M – $500.00M | Raised |
| Jul 27, 2023 | Revenue | FY2023 | $2.86B – $2.90B | Raised |
| Apr 26, 2023 | Expansion capital expenditures | FY2023 | $350.00M – $400.00M | Raised |
| Apr 26, 2023 | Maintenance capital expenditures | FY2023 | $40.00M – $50.00M | Lowered |
| Apr 26, 2023 | IT capital expenditures | FY2023 | $35.00M – $45.00M | Lowered |
| Apr 26, 2023 | Adjusted EBITDA | FY2023 | $635.00M – $675.00M | Reaffirmed |
| Apr 26, 2023 | Adjusted earnings per diluted share | FY2023 | $3.10 – $3.40 | Reaffirmed |
| Apr 26, 2023 | Tax rate | FY2023 | 25% – 26% | Reaffirmed |
| Apr 26, 2023 | Interest expense | FY2023 | $80.00M – $85.00M | New |
| Apr 26, 2023 | Depreciation and amortization expense | FY2023 | $125.00M – $135.00M | Raised |
| Apr 26, 2023 | Stock compensation expense | FY2023 | $30.00M – $35.00M | Lowered |
| Apr 26, 2023 | Operating cash flows | FY2023 | $450.00M – $500.00M | Raised |
| Apr 26, 2023 | Revenue | FY2023 | $2.82B – $2.88B | New |
| Feb 27, 2023 | Expansion capital expenditures | FY2023 | $350.00M – $400.00M | New |
| Feb 27, 2023 | Maintenance capital expenditures | FY2023 | $40.00M – $50.00M | Lowered |
| Feb 27, 2023 | IT capital expenditures | FY2023 | $35.00M – $45.00M | Lowered |
| Feb 27, 2023 | Adjusted EBITDA | Q1 FY2023 | $145.00M – $150.00M | New |
| Feb 27, 2023 | Adjusted EBITDA | FY2023 | $635.00M – $675.00M | New |
| Feb 27, 2023 | Adjusted earnings per diluted share | Q1 FY2023 | $0.70 – $0.74 | New |
| Feb 27, 2023 | Adjusted earnings per diluted share | FY2023 | $3.10 – $3.40 | New |
| Feb 27, 2023 | Tax rate | FY2023 | 25% – 26% | New |
| Feb 27, 2023 | Interest expense | FY2023 | $80.00M – $85.00M | New |
| Feb 27, 2023 | Depreciation and amortization expense | FY2023 | $125.00M – $135.00M | Raised |
| Feb 27, 2023 | Stock compensation expense | FY2023 | $30.00M – $35.00M | Lowered |
| Feb 27, 2023 | Operating cash flows | FY2023 | $450.00M – $500.00M | Raised |
| Feb 27, 2023 | Revenue | Q1 FY2023 | $690.00M – $700.00M | New |
| Feb 27, 2023 | Revenue | FY2023 | $2.82B – $2.88B | New |
| Oct 31, 2022 | Expansion capital expenditures | FY2022 | $210.00M – $230.00M | Raised |
| Oct 31, 2022 | Maintenance capital expenditures | FY2022 | $60.00M | Lowered |
| Oct 31, 2022 | Adjusted EBITDA, including income from the PRF | FY2022 | $611.00M – $621.00M | Raised |
| Oct 31, 2022 | Adjusted EBITDA, excluding income from the PRF | FY2022 | $595.00M – $605.00M | Lowered |
| Oct 31, 2022 | Adjusted earnings per diluted share, including income from the PRF | FY2022 | $3.13 – $3.23 | Raised |
| Oct 31, 2022 | Adjusted earnings per diluted share, excluding income from the PRF | FY2022 | $3.00 – $3.10 | Lowered |
| Oct 31, 2022 | Tax rate | FY2022 | 25% – 26% | Reaffirmed |
| Oct 31, 2022 | Interest expense | FY2022 | $70.00M | Lowered |
| Oct 31, 2022 | Depreciation and amortization expense | FY2022 | $120.00M | Raised |
| Oct 31, 2022 | Stock compensation expense | FY2022 | $30.00M | Lowered |
| Oct 31, 2022 | Operating cash flows | FY2022 | $360.00M – $400.00M | Raised |
| Oct 31, 2022 | Revenue | FY2022 | $2.58B – $2.60B | Raised |
| Jul 27, 2022 | Expansion capital expenditures | FY2022 | $240.00M – $280.00M | Raised |
| Jul 27, 2022 | Maintenance capital expenditures | FY2022 | $50.00M | Lowered |
| Jul 27, 2022 | Adjusted EBITDA, including income from PRF | FY2022 | $591.50M – $621.50M | Raised |
| Jul 27, 2022 | Adjusted EBITDA, excluding income from PRF | FY2022 | $583.00M – $613.00M | Lowered |
| Jul 27, 2022 | Adjusted earnings per diluted share, including income from PRF | FY2022 | $3.00 – $3.25 | Raised |
| Jul 27, 2022 | Adjusted earnings per diluted share, excluding income from PRF | FY2022 | $2.93 – $3.18 | Lowered |
| Jul 27, 2022 | Tax rate | FY2022 | 25% – 26% | Reaffirmed |
| Jul 27, 2022 | Interest Expense | FY2022 | $67.00M – $70.00M | Raised |
| Jul 27, 2022 | Depreciation and amortization expense | FY2022 | $120.00M – $125.00M | Raised |
| Jul 27, 2022 | Stock compensation expense | FY2022 | $30.00M | Lowered |
| Jul 27, 2022 | Operating cash flows | FY2022 | $380.00M – $430.00M | Raised |
| Jul 27, 2022 | Revenue | FY2022 | $2.56B – $2.60B | New |
| May 3, 2022 | Maintenance capital expenditures | FY2022 | $50.00M | Lowered |
| May 3, 2022 | Expansion capital expenditures | FY2022 | $290.00M – $340.00M | New |
| May 3, 2022 | Adjusted EBITDA | FY2022 | $575.00M – $610.00M | Reaffirmed |
| May 3, 2022 | Adjusted earnings per diluted share | FY2022 | $2.85 – $3.15 | Reaffirmed |
| May 3, 2022 | Operating cash flows, including $39 million of CARES Act repayments | FY2022 | $350.00M – $400.00M | Raised |
| May 3, 2022 | Stock compensation expense | FY2022 | $30.00M | Reaffirmed |
| May 3, 2022 | Interest Expense | FY2022 | $65.00M – $70.00M | Lowered |
| May 3, 2022 | Depreciation and amortization expense | FY2022 | $120.00M – $130.00M | Raised |
| May 3, 2022 | Tax rate | FY2022 | 25% – 26% | Reaffirmed |
| May 3, 2022 | Revenue | FY2022 | $2.55B – $2.60B | Reaffirmed |
| Feb 28, 2022 | Expansion capital expenditures | FY2022 | $290.00M – $340.00M | New |
| Feb 28, 2022 | Maintenance capital expenditures | FY2022 | $50.00M | Lowered |
| Feb 28, 2022 | Adjusted EBITDA | FY2022 | $575.00M – $610.00M | New |
| Feb 28, 2022 | Adjusted EBITDA | Q1 FY2022 | $130.00M – $135.00M | New |
| Feb 28, 2022 | Adjusted earnings per diluted share | Q1 FY2022 | $0.62 – $0.66 | New |
| Feb 28, 2022 | Adjusted earnings per diluted share | FY2022 | $2.85 – $3.15 | New |
| Feb 28, 2022 | Tax rate | FY2022 | 25% – 26% | New |
| Feb 28, 2022 | Stock compensation expense | FY2022 | $30.00M | New |
| Feb 28, 2022 | Interest Expense | FY2022 | $65.00M – $70.00M | New |
| Feb 28, 2022 | Depreciation and amortization expense | FY2022 | $120.00M – $130.00M | Raised |
| Feb 28, 2022 | Operating cash flows, including $39 million of CARES Act repayments | FY2022 | $350.00M – $400.00M | Raised |
| Feb 28, 2022 | Revenue | Q1 FY2022 | $600.00M – $610.00M | New |
| Feb 28, 2022 | Revenue | FY2022 | $2.55B – $2.60B | New |
| Oct 28, 2021 | Total capital expenditures | FY2021 | $210.00M – $230.00M | New |
| Oct 28, 2021 | Adjusted EBITDA | FY2021 | $537.00M – $547.00M | New |
| Oct 28, 2021 | Adjusted earnings per diluted share | FY2021 | $2.51 – $2.59 | New |
| Oct 28, 2021 | stock compensation expense | Q4 FY2021 | $11.00M – $13.00M | New |
| Oct 28, 2021 | Operating cash flows | FY2021 | $290.00M – $325.00M | New |
| Oct 28, 2021 | Revenue | FY2021 | $2.30B – $2.32B | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Acadia Healthcare filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- Results
- Results
- Results
- Update
- Update
- Results
- Results
- Update
- Results
- Update
- Results
- Update